|
楼主 |
发表于 2013-9-7 21:16:56
|
显示全部楼层
来自: 中国江苏南京
Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker.J Natl Cancer Inst 2013 Jul 105 14 :1036-1042
Sgroi DC Carney E Zarrella E Steffel L Binns SN Finkelstein DM Szymonifka J Bhan AK Shepherd LE Zhang Y Schnabel CA Erlander MG Ingle JN Porter P Muss HB Pritchard KI Tu D Rimm DL Goss PE
Affiliations of authors: Department of Pathology, Molecular Pathology Unit, Massachusetts General Hospital, Charlestown, MA (DCS, EC, EZ, LOS, SNB, AKB); Department of Pathology and Medicine, Center for Cancer Research, Massachusetts General Hospital, Boston, MA (DCS, EC, EZ, LS, SNB, DMF, JS, PEG); NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada (LES, DT, KIP); bioTheranostics, Inc, San Diego, CA (YZ, CAS, MGE); Mayo Clinic, Rochester, MN (JNI); Human Biology Department, Fred Hutchinson Cancer Research Center, Seattle, WA (PP); Department of Medicine, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC (HBM); Department of Medicine, Sunnybrook Odette Cancer Center, University of Toronto, Toronto, ON, Canada (KIP); Department of Pathology, Yale University School of Medicine, New Haven, CT (DLR).
|
|